# Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

> **NCT06861218** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Leptomeningeal Metastases

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** vometinib

## Key facts

- **NCT ID:** NCT06861218
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2028-05
- **Final completion:** 2028-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861218, "Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06861218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*